Hypertension and kidneys: Unraveling complex molecular mechanisms underlying hypertensive renal damage

Journal of Human Hypertension

Volumn 28, Issue 2, 2014, Pages 74-79

  Mennuni, S ^a   Rubattu, S ^a,b   Pierelli, G ^a   Tocci, G ^b   Fofi, C ^a   Volpe, M ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Genetics; Hypertension; Inflammation; Kidney damage; Oxidative stress; Renin angiotensin system

Indexed keywords

ANTIHYPERTENSIVE AGENT; RENIN ANGIOTENSIN ALDOSTERONE INHIBITOR; UNCLASSIFIED DRUG; URINARY TRACT AGENT;

ENDOTHELIAL DYSFUNCTION; EPIGENETICS; GENETICS; HUMAN; HYPERTENSION; KIDNEY INJURY; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; KIDNEY; KIDNEY DISEASES; OXIDATIVE STRESS; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84891845736     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.55     Document Type: Review

References (35)

1. U.S. Renal Data System. USRDS 2009 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2009.
2. Segura J, Campo C, Gil P, Roldan C, Vigil L, Rodicio JL et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616-1622.
3. Olson JL. Renal disease caused by hypertension. In: Jennette JC et al. Heptinstall's Pathology of the kidney. 6th edn Lippincott Williams & Wilkins: Phyladelphia, PA, USA, pp 937-988, 2007.
4. Folkow B, Gothberg G, Lundin S, Ricksten SE. Structural resetting of the renal vascular bed in spontaneously hypertensive rats (SHR). Acta Physiol Scand 1977; 100: 270-272.
5. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
6. Shankland SJ. The podocyte's response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
7. Eddy A. Proteinuria and interstitial injury. Nephrol Dial Transplant 2004; 19: 277-281.
8. Fofi C, Pecci G, Galliani M. IgA nephropathy: multivariate statistical analysis aimed at predicting outcome. J Nephrol 2001; 14: 280-285.
9. Romagnani P, Remuzzi G. Renal progenitors in non-diabetic and diabetic nephropathies. Trends Endocrinol Metab 2013; 24: 13-20.
10. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991.
11. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645-651.
12. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003; 93: P3-P13.
13. Thomas WG, Thekkumkara TJ, Baker KM. Molecular mechanisms of angiotensin II (AT1A) receptor endocytosis. Clin Exp Pharmacol Physiol Suppl 1996; 3: S74-S80.
14. Queisser N, Oteiza PI, Stopper H, Oli RG, Schupp N. Aldosterone induces oxidative stress, oxidative DNA damage and NF-kB-activation in kidney tubule cells. Mol Carcinog 2011; 50: 123-135.
15. Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 2006; 36(Suppl 3): 78-88.
16. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005; 289: R913-R935.
17. Di Castro S, Scarpino S, Marchitti S, Bianchi F, Stanzione R, Cotugno M et al. Differential modulation of uncoupling protein 2 in kidneys of strokeprone spontaneously hypertensive rats under high-salt/low-potassium diet. Hypertension 2013; 61: 534-541.
18. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 2013; 99(11): 759-766.
19. Baylis C. Nitric oxide synthase derangements and hypertension in kidney disease. Curr Opin Nephrol Hypertens 2012; 21: 1-6.
20. Ponnuchamy B, Raouf A. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 2009; 296: R1001-R1018.
21. Doris PA. Genetic susceptibility to hypertensive renal disease. Cell Mol Life Sci 2012; 69: 3751-3763.
22. Schulz A, Kreutz R. Mapping genetic determinants of kidney damage in rat models. Hypertens Res 2012; 35: 675-694.
23. Turner ST, Kardia SL, Mosley TH, Rule AD, Boerwinkle E, de Andrade M. Influence of genomic loci on measures of chronic kidney disease in hypertensive sibships. J Am Soc Nephrol 2006; 17: 2048-2055.
24. DeWan AT, Arnett DK, Miller MB, Peacock JM, Atwood LD, Province MA et al. Refined mapping of suggestive linkage to renal function in African Americans: the HyperGEN study. Am J Hum Genet 2002; 71: 204-205.
25. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010; 6: e1001177.
26. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL et al. New loci associated with kidney function and chronic kidney disease. Nat. Genet 2010; 42: 376-384.
27. Drawz PE, Sedor JR. The genetics of common kidney disease: a pathway toward clinical relevance. Nat Rev Nephrol 2011; 7: 458-468.
28. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184.
29. Arrondel C, Vodovar N, Knebelmann B, Grunfeld JP, Gubler MC, Antignac C et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 2002; 13: 65-74.
30. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
31. Heggermont WA, Heymans S. MicroRNA are involved in end-organ damage during hypertension. Hypertension 2012; 60: 1088-1093.
32. Macconi D, Tomasoni S, Romagnani P, Trionfini P, Sangalli F, Mazzinghi B et al. MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol 2012; 23: 1496-1505.
33. Tocci G, Volpe M. End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function. Drugs 2011; 71: 1003-1017.
34. Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.
35. Benigni A, Morigi M, Rizzo P, Gagliardini E, Rota C, Abbate M et al. Inhibiting ACE promotes renal repair by limiting progenitor cells proliferation and restoring the glomerular architecture. Am J Pathol 2011; 179: 628-638.